Transmitter dysfunction during the process of schizophrenia

Acta Psychiatrica Scandinavica, Supplement

Volumn 99, Issue 395, 1999, Pages 105-112

  Glenthøj, Birte Y ^a   Hemmingsen, R ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Behavioural sensitization; Corticostriato thalamocortical circuits; Dopamine; Glutamate; Schizophrenia; Sensorimotor gating; Serotonin

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SERTINDOLE; ZIPRASIDONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DOPAMINE; GLUTAMIC ACID; SEROTONIN;

COGNITIVE DEFECT; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; KINDLING; NEGATIVE SYNDROME; NEUROTRANSMITTER RELEASE; PATHOPHYSIOLOGY; PERCEPTION; RECEPTOR SENSITIVITY; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; ANIMAL; BRAIN; CORPUS STRIATUM; DEFENSE MECHANISM; LIMBIC SYSTEM; NERVE CELL INHIBITION; NERVE TRACT; PERCEPTIVE THRESHOLD; PHYSIOLOGY; PREFRONTAL CORTEX; REVIEW; TEMPORAL LOBE; THALAMUS;

ANIMALS; BRAIN; CORPUS STRIATUM; DOPAMINE; GLUTAMIC ACID; HUMANS; LIMBIC SYSTEM; NEURAL INHIBITION; NEURAL PATHWAYS; NEUROTRANSMITTER AGENTS; PREFRONTAL CORTEX; REPRESSION-SENSITIZATION; SCHIZOPHRENIA; SENSORY THRESHOLDS; SEROTONIN; TEMPORAL LOBE; THALAMUS;

EID: 0033065864     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1999.tb05989.x     Document Type: Conference Paper

References (81)

1. CARLSSON A. Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 1978;135:164-173.
2. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-76.
3. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 1989;99:28-31.
4. GALLHOFER B, BAUER U, LIS S, KRIEGER S, GRUPPE H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996;6:13-20.
5. GRACE J, BELLUS SB, RAULIN ML et al. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr Services 1996;47:41-45.
6. ARNOLD SE, HYMAN BT, VAN HOUSE GW, DAMASIO AR. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 1991;48:625-632.
7. ARNOLD SE, FRANZ BR, GUR RC, SHAPIRO RM, MOBERG PJ, TROJANOWSKISKI JQ. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am J Psychiatry 1995;152:738-748.
8. AKBARIAN S, VINUELA A, KIM JJ, POTKIN SG, BUNNEY WE, JONES EG. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993;50:178-187.
9. AKBARIAN S, BUNNEY WE, POTKIN SG et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993;50:169-177.
10. BLOOM FE. Advancing a neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 1993;50:224-227.
11. PAKKENBERG B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenia. Arch Gen Psychiatry 1990;47:1023-1028.
12. ANDREASEN NC, ARNDT ST, SWAYZE II V et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994;266:294-308.
13. BUCHSBAUM MS, SOMEYA T, TENG CY et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiatry 1996;153:191-199.
14. LIPSKA BK, JASKIW GE, WEINBERGER DR. The effects of combined prefrontal cortical and hippocampal damage on dopamine-related behaviors in rats. Pharmacol Biochem Behav 1994;48:1053-1057.
15. GLENTHØJ BY, HEMMINGSEN R. Dopaminergic sensitization: implication for the pathogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1997;21:23-46.
16. GLENTHØJ B, MOGENSEN J, LAURSEN H, HEMMINGSEN R. Dopaminergic sensitization of rats with and without early prefrontal lesions: implications for the pathogenesis of schizophrenia. Unpublished data.
17. GLENTHØJ B, MOGENSEN J, LAURSEN H, HOLM S, HEMMINGSEN R. Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia. Brain Res 1993;619:39-54.
18. GLENTHØJ B. The brain dopaminergic system: pharmacological, behavioural and electrophysiological studies. Dan Med Bull 1995;42:1-21.
19. COHEN JD, SERVAN-SCHREIBER D. A theory of dopamine function and its role in cognitive deficits in schizophrenia. Schizophr Bull 1993;19:85-104.
20. SPITZER M. The psychopathology, neuropsychology and neurobiology of associative and working memory in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1993;243:57-70.
21. JOYCE JN. The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology 1993;112:16-34.
22. CRAWLEY JCW, CROW TJ, JOHNSTONE EC et al. Dopamine receptors in schizophrenia studied in vivo. Lancet 1986;2:224-225.
23. CRAWLEY JCW, CROW TJ, JOHNSTONE EC et al. Uptake of Br-spiperone in the striata of schizophrenic patients and controls. Nucl Med Commun 1986;7:599-607.
24. 2-dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 1990;47:231-219.
25. 11C]methylspiperone and PET. J Cereb Blood Flow Metab 1985;5(Suppl. 1):191-192.
26. 2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994;51:116-123.
27. 76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry 1990;147:44-50.
28. 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 1994;164:16-26.
29. 2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-1563.
30. REYNOLDS GP, CZUDEK C, ANDREWS HB. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatry 1990;27:1038-1044.
31. LOUILOT A, LE MOAL M. Lateralized interdependence between limbicotemporal and ventrostriatal dopaminergic transmission. Neuroscience 1994;59:495-500.
32. PRALONG E, JONES RS. Interactions of dopamine with glutamate- and GABA-mediated synaptic transmission in the rat entorhinal cortex in vitro. Eur J Neurosci 1993;5:760-767.
33. SCHEEL-KRÜGER J, WILLNER P. The mesolimbic system: principles of operation. In: WILLNER P, SCHEEL-KRÜGER J, ed. The mesolimbic dopamine system. From motivation to action. Chichester: John Wiley & Sons Ltd, 1991:559-597.
34. REITH J, BENKELFAT C, SHERWIN A et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Neurobiology 1994;91:11651-11654.
35. LlEBERMAN JA, KANE JM, GADALETA D, BRENNER R, LESSER MS, KINON B. Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry 1984;141:633-638.
36. LIEBERMAN JA, KANE JM, SARANTAKOS S et al. Prediction of relapse in schizophrenia. Arch Gen Psychiatry 1987;44:597-603.
37. LIEBERMANN JA, KINON BJ, LOEBEL AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull 1990;16:97-110.
38. JANOWSKY DS, KHALED EL-YOUSEF M, DAVIS JM, SEKERKE HJ. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 1973;28:185-1991.
39. LEVY DL, SMITH M, ROBINSON D. Methylphenidate increases thought disorder in recent-onset schizophrenics, but not in normal controls. Biol Psychiatry 1993;4:507-514.
40. HARACZ JL. An overview of studies with schizophrenic patients. Schizophr Bull 1982;8:438-479.
41. HEMMINGSEN R, GLENTHØJ B, RUBIN P. Maltunement of the cortical network in schizophrenia: association of psychopathology and neurobiology. In: FOG R, GERLACH J, HEMMINGSEN R, ed. Schizophrenia. Alfred Benzon Symposium No. 38. Copenhagen: Munksgaard, 1995:60-70.
42. SATO M, NUMACHI Y, HAMAMURA T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 1992;18:115-121.
43. GODDARD GV, MCINTYRE DC, LECH CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurology 1969;25:295-330.
44. GRACE AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:124.
45. KALIVAS PW, WEBER B. Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine. J Pharmacol Exp Ther 1988;245:1095-1102.
46. CAVALHEIRO EA, FERNANDES MJ, TURSKI L, NAFFAH-MASSACORATTI MG. Spontaneous recurrent seizures in rats: amino acid and monoamine. Epilepsia 1994;35:1-11.
47. HARRISON PJ, MCLAUGHLIN D, KERWIN RW. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 1991;337:450-452.
48. 2 receptor mRNA expression in basal ganglia following kindling. Epilepsy Res 1994;17:23-29.
49. KERWIN RW, PATEL S, MELDRUM BS, CZUDEK C, REYNOLDS G. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet 1988;i:583-584.
50. KERWIN RW, PATEL S, REYNOLDS GP. Autoradiographic localization of the glutamate receptor system in control and schizophrenic post-mortem hippocampal formation. Neuroscience 1990;39:25-32.
51. SIMPSON MDC, ROYSTON MC, SLATER P, DEAKIN JFW. Phencyclidine and sigma receptor abnormalities in schizophrenic post-mortem brain. Schizophr Res 1990;3:32 (abstract VB2).
52. WEISSMANN AD, CASANOVA MF, KLEINMANN JE, LONDON E, DESOUZA EB. Selective losses of cerebral cortical sigma but not PCP binding sites in schizophrenia. Biol Psychiatry 1991;29:41-54.
53. DEAKIN JFW, SLATER P, SIMPSON MDC, GILCHIST AC, SKAN WJ. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989;52:1781-1786.
54. ISHIMARU M, KURUMAJI A, TORU M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for the glutamate hypothesis. Biol Psychiatry 1994;35:84-95.
55. LODGE D, ANIS NA. Effect of phencyclidine on excitatory amino acid activation of spinal interneurons in the cat. Eur J Pharmacol 1982;77:203-204.
56. LODGE D, ARAM JA, CHUCH J et al. Excitatory amino acids and phencyclidine-like drugs. In: HIKS TP, LODGE D, MCLENNAN H, ed. Excitatory amino acid transmission. New York: Alan R. Liss Inc., 1987:83-90.
57. KRYSTAL JH, KARPER LP, SEIBYL JP. Subanaesthetic effects of the noncompetitive, NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
58. OLNEY JW, FARBER NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
59. ULAS J, NGUYEN L, COTMAN CW. Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. NeuroReport 1993;4:1049-1051.
60. BANERJEE SP, ZUCK LG, YABLONSKY-ALTER E, LIDSKY TI. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. NeuroReport 1995;6:2500-2504.
61. YAMAMOTO BK, COOPERMAN MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994;14:4159-4166.
62. BARDGETT ME, WRONA CT, NEWCOMER JW, CSERNANSKY JG. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur J Pharmacol 1993;230:245-250.
63. TARAZI FI, FLORIJN WJ, CREESE I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 1996;128:371-379.
64. OHUOHA DC, HYDE TM, KLEINMAN JE. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology 1993;112:5-15.
65. JOYCE JN, SHANE A, LEXOW N, WINOKUR A, CASANOVA MF, KLEINMAN JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993;8:315-336.
66. KAHN RS, DAVIDSON M, KNOTT P, STERN RG, APTER S, DAVIS KL. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch Gen Psychiatry 1993;50:599-605.
67. 2 receptor blocking agent, ritanserin, in the rat. Eur Neuropsychopharmacol 1996;6:305-310.
68. MCGHIE A, CHAPMAN J. Disorders of attention and perception in early schizophrenia. Br J Med Psychol 1961;34:103-117.
69. CARLSSON A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-186.
70. ALEXANDER GE. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.
71. ALEXANDER GE, CRUTCHER MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-271.
72. ALEXANDER CE, CRUTCHER MD, DELONG MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, 'prefrontal' and 'limbic' functions. Progr Brain Res 1990;85:119-146.
73. MOGHADDAM B, GRUEN RJ, ROTH RH, BUNNEY BS, ADAMS RN. Effect of L-glutamate on the release of striatal dopamine: in vivo dialysis and electrochemical studies. Brain Res 1990;518:55-60.
74. WEISS F, PAULUS MP, LORANG MT, KOOB GF. Increases in extracellular dopamine in the nucleus accumbens by cocaine are inversely related to basal levels: effects of acute and repeated administration. J Neurosci 1992;12:4372-4380.
75. GRENHOFF J. Firing pattern in midbrain dopamine neurons. A pharmacological study in the rat. Stockholm: Department of Pharmacology, Karolinska Institute, 1990.
76. GRENHOFF J, TUNG GS, SVENSSON TH. The excitatory amino acid antagonist kynurenate induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol Scand 1988;134:567-568.
77. MURASE S, GRENHOFF J, CHOUVET G, GONON FG, SVENSSON TH. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett 1993;157:53-6.
78. SVENSSON TH, ENGBERG G, TUNG C-S, GRENHOFF J. Pacemaker-like firing of noradrenergic locus coeruleus neurons in vivo induced by the excitatory amino acid antagonist kynurenate in the rat. Acta Physiol Scand 1989;135:421-422.
79. 2 receptors in schizophrenia and antipsychotic activity. Int Clin Psychopharmacol 1993;8 (Suppl.):25-32.
80. 1-adrenoreceptor. J Clin Pharmacol 1995;15:11-18.
81. GRAHAM SR, KOKKINIDIS L. Clozapine inhibits limbic system kindling: implications for antipsychotic action. Brain Res Bull 1993;30:597-605.